Singapore's Ministry of Health has issued a directive that allows the OraQuick Rapid HIV 1/2 Antibody Test Kits, developed by USA-based OraSure Technologies, to be used at all clinics in the country. The kit uses oral fluid for analysis in needle-free process, which is designed for patient convenience, that can produce definitive results in around 20 minutes.
Additionally, the directive permits the use of the OraQuick kit in the mandatory testing of foreign nationals who are seeking, or renewing, work permits. Douglas Michaels, chief executive of OraSure, welcomed the news, commented that its product, distributed by local firm Rockeby biomed, would make a substantial contribution towards HIV detection in Singapore.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze